Abstracts Archive - Page 1414 of 2607 - ACR Meeting Abstracts

Abstract Number: 401 • 2017 ACR/ARHP Annual Meeting
Cigarette Smoking Dose-Dependently Facilitates the Onset of Arthritis and Aggravates Arthritis in Female Experimental Arthritis Mice
Ji-Won Kim¹, Jennifer Lee², Yeon-Sik Hong³, Sung-Hwan Park² and Ji Hyeon Ju², ¹Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Smoking is an important epidemiological factor for development of rheumatoid arthritis (RA). However, the mechanism of proarthritic role of smoking is not well understood.…
Abstract Number: 402 • 2017 ACR/ARHP Annual Meeting
Alteration of the Intestinal Microbiome in the Preclinical Phase of Experimental Arthritis and the Efficacy of Microbiota Modulation in Established Arthritis in Mice
Rebecca Rogier¹, Heather Evans-Marin², Julia Manasson³, Peter M. van der Kraan⁴, Wim B. van den Berg⁵, Marije I. Koenders⁴, Jose U. Scher⁶ and Shahla Abdollahi-Roodsaz^7,8, ¹Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²Division of Rheumatology, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Radboud University Medical Center, Nijmegen, Netherlands, ⁶New York University School of Medicine, New York, NY, ⁷Department of Medicine, Division of Rheumatoogy, New York University School of Medicine, New York, NY, ⁸Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: The composition of intestinal microbiota is perturbed in patients with new-onset and chronic rheumatoid arthritis (RA). However, it is not known whether the changes…
Abstract Number: 403 • 2017 ACR/ARHP Annual Meeting
Cardiac Immune Cells in SKG Mice with Inflammatory Arthritis before and after Myocardial Infarction
Christine Hsieh¹, Isabella Imhof², Luyi Li³, Erene Niemi¹, Matthew Bell¹, Joel Karliner⁴ and Mary Nakamura⁵, ¹Medicine, SFVA/UCSF, San Francisco, CA, ²Medicine, SFVA/NCIRE, San Francisco, CA, ³SFVA/UCSF, San Francisco, CA, ⁴Medicine, SFVA/UCSF, San, CA, ⁵Department of Medicine, Division of Rheumatology, UCSF/SFVA, San Francisco, CA
Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in patients with rheumatoid arthritis (RA). RA patients have an increased incidence of both…
Abstract Number: 404 • 2017 ACR/ARHP Annual Meeting
Gut Microbiota Modify Inflammatory Arthritis through Autoantibody Generation and Mucosal Cytokines Alteration
Widian Jubair¹, Sumitra Adhikari², Nirmal Banda² and Kristine Kuhn³, ¹Rheumatology, University of Colorado, Aurora, CO, ²Division of Rheumatology, UC Denver School of Medicine, Denver, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is thought to be influenced by a combination of genetic and environmental factors. Observations of microbial dysbiosis in…
Abstract Number: 405 • 2017 ACR/ARHP Annual Meeting
Dynamics of Transcriptional Signatures from Purified Synovial Macrophage Subsets during Acute and Chronic Murine Models of Inflammatory Arthritis
Philip J. Homan, Salina Dominguez, Harris Perlman, Deborah R. WInter and Carla Cuda, Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) manifests in persistent synovial inflammation, cellular infiltration and pro-inflammatory cytokine production, resulting in progressive joint destruction. Macrophages have been implicated in…
Abstract Number: 406 • 2017 ACR/ARHP Annual Meeting
Mapping Changes in Monocyte and Macrophage Populations in the Synovium: An Aging Study in Arthritic KRN Ag7 Mice
Anna B Montgomery¹, Carla Cuda², Philip J. Homan³, Harris Perlman² and Deborah R. WInter², ¹Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of the joints associated with accelerated aging and increased mortality. Further, RA is linked with a number…
Abstract Number: 407 • 2017 ACR/ARHP Annual Meeting
Selective Inhibition of Tfh Cells By a Small Molecule Inhibitor Abrogates Progression of Experimental Inflammatory Arthritis
Frank Migliore¹, Sedrick Bradley¹, Linh Hellmers¹, Quretul Quresh², Jerald M. Zakem³, William E. Davis³, Tamika Webb-Detiege¹, Zongbing You⁴, Robert Quinet² and Xin Zhang⁵, ¹Ochsner Clinic Foundation, New Orleans, LA, ²Rheumatology, Ochsner Medical Center, New Orleans, LA, ³University of Queensland School of Medicine, Brisbane, Australia, ⁴Tulane University Health Science Center, New Orleans, LA, ⁵Laboratory of Cellular Immunology, Institution of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized by progressive infiltration of the joints by T cells and other leukocytes, production of…
Abstract Number: 408 • 2017 ACR/ARHP Annual Meeting
CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis
Gianfranco Caselli¹, Flora Ferrari¹, Eleonora Comi¹, Marco Perrella¹, Camilla Recordati², Adriana Grotti¹, Rosanna Cavagnoli¹, Marco Lanza¹ and Lucio C. Rovati³, ¹Rottapharm Biotech, Monza, Italy, ²Mouse & Animal Pathology Lab,, Fondazione Filarete, Milano, Italy, Milano, Italy, ³Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086, a selective EP4 antagonist, dose-dependently improves disease features in rheumatoid arthritis (RA) models in rodents. Indeed, recent studies highlight the role of the…
Abstract Number: 409 • 2017 ACR/ARHP Annual Meeting
An Evaluation of Absolute Neutrophil Count As a Biomarker of Inflammatory and Clinical Disease Activity in Baricitinib-Treated Patients
Iain B. McInnes¹, Lee S. Simon², Robert J. Moots³, Vipin K. Arora⁴, John D. Bradley⁴ and David Muram⁴, ¹University of Glasgow, Glasgow, United Kingdom, ²SDG LLC, Cambridge, MA, ³University of Liverpool, Liverpool, UK, Liverpool, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) tend to have higher absolute neutrophil count (ANC) values compared to healthy individuals.1 Baricitinib (BARI), an oral, selective Janus…
Abstract Number: 410 • 2017 ACR/ARHP Annual Meeting
Association between Anti-Citrullinated Protein Antibody Status and the Incidence of Erosive Disease in Patients with RA
Leslie R Harrold¹, Heather J. Litman², SE Connolly³, E Alemao³, Sabrina Rebello⁴, W Hua² and Joel Kremer⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, Southborough, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: RA is characterized by the production of autoantibodies including anti-citrullinated protein antibodies (ACPAs).1 ACPAs are considered a prognostic indicator for more severe RA and…
Abstract Number: 411 • 2017 ACR/ARHP Annual Meeting
Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience
César Sifuentes-Cantú¹, Irazu Contreras-Yañez², Lina Saldarriaga Rivera³, Ana Cecilia Lozada⁴, Marwin Gutierrez⁵ and Virginia Pascual-Ramos¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Instituto Nacional de Rehabilitación, Mexico, Mexico, ⁴Division of musculoskeletal and rheumatic diseases, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁵Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico
Background/Purpose: The management plan for rheumatoid arthritis (RA) might be a relatively simple task if only disease activity is considered but might become more complex…
Abstract Number: 412 • 2017 ACR/ARHP Annual Meeting
Baseline Values for Plantar Pressure and Background Characteristics As Indicators for the Limit of Conservative Treatment of Rheumatoid Forefoot Deformity
Hyunho Lee¹, Hajime Ishikawa¹, Asami Abe¹, Yumi Nomura¹, Eriko Hasegawa¹, Chinatsu Takai¹, Daisuke Kobayashi¹, Hiroshi Otani¹, Satoshi Ito¹, Takanobu Sumino², Takao Ishii², Shu Saito³, Yasuaki Tokuhashi⁴, Kiyoshi Nakazono¹ and Akira Murasawa¹, ¹Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Department of Orthopaedic Surgery, Kawaguchi Municipal Medical Center, Kawaguchi, Japan, ³Department of Orthopaedic Surgery, Nihon University School of Medicine, Itabishi, Japan, ⁴Department of Orthopaedic Surgery, Nihon University School of Medicine, Itabiashi, Japan
Background/Purpose: Forefoot deformities are commonly seen in patients with RA. It has been reported that nearly 90% of the patients have foot problems.1,2 Patients with…
Abstract Number: 413 • 2017 ACR/ARHP Annual Meeting
Economic Burden Associated with Anti-Cyclic Citrullinated Peptide Antibody Positivity in Patients Newly Diagnosed with RA
J An¹, Z Bider², J Kang¹, E Alemao³, SE Connolly³ and TC Cheetham¹, ¹Western University of Health Sciences, Pomona, CA, ²Southern California Permanente Medical Group, Pasadena, CA, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibody positivity has been suggested as a strong predictor of joint erosion as well as a potential biomarker for guiding…
Abstract Number: 414 • 2017 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission
Melanie Hagen¹, Matthias Englbrecht², Judith Haschka³, Michaela Reiser⁴, Arnd Kleyer⁵, Axel J. Hueber⁶, Bernhard Manger⁷, Camille Figueiredo⁸, Jayme Fogagnolo Cobra⁹, Hans-Peter Tony¹⁰, Stefanie Finzel¹¹, Stefan Kleinert¹², Joerg Wendler¹³, Florian Schuch¹³, Monika Ronneberger¹³, Martin Feuchtenberger¹⁴, Martin Fleck^15,16, Karin Manger¹⁷, Matthias Schmitt-Haendle¹⁸, H.-M. Lorenz¹⁹, HG Nüßlein²⁰, Rieke Alten²¹, Joerg C. Henes²², Klaus Krüger²³, Georg Schett² and Juergen Rech²⁴, ¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ³Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ⁶Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Institution de Rheumatologia, Sao Paolo, Brazil, ⁹Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ¹⁰Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ¹¹University of Freiburg, Freiburg, Germany, ¹²Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ¹³Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ¹⁵Department of Rheumatology and Clinical Immunology, Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, ¹⁶Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany, ¹⁷Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁸Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, ¹⁹Rheumatology, University Heidelberg, Heidelberg, Germany, ²⁰Rheumatology Practice Nuremberg, Nuremberg, Germany, ²¹Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ²²Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²³Praxiszentrum St.Bonifatius, Munich, Germany, ²⁴Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…
Abstract Number: 415 • 2017 ACR/ARHP Annual Meeting
Baricitinib Reduces GlycA Levels in Phase 2 and Phase 3 Clinical Trials in Patients with Moderate to Severe Rheumatoid Arthritis
Joel Kremer¹, Paul Emery², Margery A. Connelly³, James D. Otvos⁴, Steven H. Zuckerman⁵, Giacomo Ruotolo⁵, Lei Chen⁵, Maher Issa⁵, William L. Macias⁵ and Iain B. McInnes⁶, ¹Albany Medical College, Albany, NY, ²Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ³Laboratory Corporation of America Holdings (LabCorp), Morrisvile, NC, ⁴Laboratory Corporation of America Holding (LabCorp), Morrisville, NC, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1/JAK2.1 In the European Union, bari is approved for the treatment of moderate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].